Chronic thromboembolic pulmonary hypertension (CTEPH)
Chronic thromboembolic pulmonary hypertension (CTEPH) may occur in about 2-4% of patients presenting with acute pulmonary embolism. It is considered when mean pulmonary artery pressure persists at or above 25 mm Hg after an episode of pulmonary thromboembolism [1]. Though it is a rare complication of pulmonary embolism, mortality and morbidity are significant. Upto 90% three year mortality has been reported in those with mean pulmonary artery pressures above 50 mm Hg. Majority of those with CTEPH may not give a history suggestive of previous presentation with acute pulmonary embolism. In those who developed CTEPH after pu...
Source: Cardiophile MD - April 24, 2020 Category: Cardiology Authors: Prof. Dr. Johnson Francis Tags: Cardiology CTEPH CTPH Source Type: blogs

Chronic thromboembolic pulmonary hypertension (CETPH)
Chronic thromboembolic pulmonary hypertension (CTEPH) may occur in about 2-4% of patients presenting with acute pulmonary embolism. It is considered when mean pulmonary artery pressure persists at or above 25 mm Hg after an episode of pulmonary thromboembolism [1]. Though it is a rare complication of pulmonary embolism, mortality and morbidity are significant. Upto 90% three year mortality has been reported in those with mean pulmonary artery pressures above 50 mm Hg. Majority of those with CETPH may not give a history suggestive of previous presentation with acute pulmonary embolism. In those who developed CETPH after pu...
Source: Cardiophile MD - April 24, 2020 Category: Cardiology Authors: Prof. Dr. Johnson Francis Tags: Cardiology CETPH CTPH Source Type: blogs

Pathways in pathogenesis of PAH – Cardiology MCQ – Answer
Pathways in pathogenesis of PAH – Cardiology MCQ – Answer Which of the following is NOT a pathway involved in the pathogenesis of pulmonary arterial hypertension (PAH)? Correct answer: 4. Pentose phosphate pathway All the other three are important pathways in the pathogenesis of PAH. Medications used in the treatment block these pathways. Endothelin pathway blockers: Bosentan, Ambrisentan, Macitentan Nitric oxide pathway: Sildenafil, Tadalafil, Vardenafil Prostacyclin pathway: Epoprostenol, Iloprost, Treprostinil, Beraprost (Prostacyclin analogues) and Selexipag (Selective IP receptor antagonist). IP receptor is ...
Source: Cardiophile MD - June 10, 2019 Category: Cardiology Authors: Prof. Dr. Johnson Francis Tags: Cardiology MCQ DM / DNB Cardiology Entrance Source Type: blogs

Did Big Pharma BUY Big Media?
Healthcare is at the top of the list of societal problems in the U.S. Healthcare interactions are unsatisfying to most people, costs are out of control and cost every American nearly $10,000 per person per year while bleeding 17.5% of GDP, more than any other nation on earth for a system that ranks low or last  in quality compared to other developed countries. For a problem as big as healthcare, big enough to cripple the entire economy in addition to bankrupting more and more Americans, you would think that media reporting would be filled with debate, criticisms, and in-depth coverage about the problems in healthcare. But...
Source: Wheat Belly Blog - May 2, 2017 Category: Cardiology Authors: Dr. Davis Tags: Undoctored abc bias big pharma cbs cnn drug industry fox gluten grains health healthcare illness media nbc pharmaceutical tv wheat Source Type: blogs

The Future of Work Part I
Have you ever taken some time to think about what work will look like 5, 10 or even 20 years from now? If you haven’t, it is probably worth the effort because a changing work environment may have dramatic implications for how you are employed in the future. In these two posts, I want to talk about some of the trends I’m seeing and how they may play out in the coming years. Outsourcing Companies are getting better and better at spinning off specific business functions and letting them be handled by others. For example, many businesses can’t justify running payroll in-house. It is cheaper to hire a company...
Source: Productivity501 - September 20, 2016 Category: Psychiatry & Psychology Authors: Mark Shead Tags: Misc Source Type: blogs

TBT: Blind to women’s sexual health
Today’s TBT post ran over two years ago and addressed female dysfunction. Given the FDA’s recent approval of flibanserin, a pill that aims to increase a woman’s desire for sex, we thought it would be helpful to review some of the early conversations on the issue. A recent article published in partnership with The Investigative Fund and Newsweek questioned the existence of “female dysfunction,” as if to say, who cares about women’s sexual health? If you can’t “see” it, apparently it doesn’t exist. This is one-sided, inaccurate and disparaging of women. Why is it that when men are impotent it ...
Source: Disruptive Women in Health Care - August 20, 2015 Category: Consumer Health News Authors: dw at disruptivewomen.net Tags: Aging Choice gender Women's Health Flibanserin Food and Drug Administration Sexual desire Sexual dysfunction Source Type: blogs

The Single Senior STD Epidemic
If you think your retired parents who have settled into a low-key retirement home or senior living community are spending their time playing checkers and watching soaps, think again! They may be running around having sex just like college kids let loose in a dorm for the first time. Senior citizens, contrary to popular belief, are often still sexually active. And they are spreading sexually transmitted diseases (STDs). According to the Center for Disease Control, since 2007, the incidence of syphilis among seniors, those 65 and over, is up by 52 percent, and the number of chlamydia cases has risen 32 percent. The rapid inc...
Source: Disruptive Women in Health Care - April 27, 2015 Category: Consumer Health News Authors: dw at disruptivewomen.net Tags: Aging Source Type: blogs

Who needs Viagra?
Yes, erectile dysfunction can reverse with the Wheat Belly lifestyle. But why and how? Erectile dysfunction, ED, and thereby erections, are fairly complicated phenomena. But the capacity to mount an erection parallels arterial health elsewhere in the body, particularly in the heart, since penile erections are a blood flow regulation phenomenon. In my cardiology practice, for instance, it was virtually the rule to see ED coupled with coronary disease, since coronary disease is essentially an expression of poor arterial function and health, also. If you have coronary disease, you likely have ED; if you have ED, you likely ha...
Source: Wheat Belly Blog - February 21, 2015 Category: Cardiology Authors: Dr. Davis Tags: Wheat Belly Lifestyle erectile dysfunction fish oil grains omega-3 sex sexual vitamin D Source Type: blogs

Intravenous Nitroglycerine in STEMI, with data: Avoid its use if giving tPA
In conclusion, concurrent nitroglycerin administration reduces the thrombolytic efficacy of rTPA in patients with AMI probably by lowering the plasma levels of rTPA antigen. The diminished efficacy of rTPA is associated with an adverse outcome.References1.         Nicolini FA, Ferrini D, Ottani F, et al. Concurrent nitroglycerine therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction. Am J Cardiol 1994; 74:662-666.2.         Mehta JL, Nicolini FA, Nichols WW, Saldeen TG. Concurre...
Source: Dr. Smith's ECG Blog - September 11, 2014 Category: Cardiology Authors: Steve Smith Source Type: blogs

Another Idea for Creating FDA-Compliant Promotional Tweets: Put the Carriage Before the Horse
In previous posts, I discussed a few different techniques that pharma marketers could use to create Rx branded promotional tweets that satisfy recently-published FDA guidelines.One such idea was to attach an image of the required important safety information (ISI) to the promotional tweet (see "A Type of Rx Drug Tweet FDA Did Not Consider in its Recent Guidance").I polled readers about this and a majority of readers who took my poll said, yes, it's possible that such a tweet would satisfy FDA guidance requirements:In discussions with the Twitter "pharma team," however, I learned that on small-screen...
Source: Pharma Marketing Blog - July 2, 2014 Category: Pharma Commentators Tags: #fdasm Cialis Drug Safety Guidance ISI social media Twitter Source Type: blogs

Study Suggests Link Between Viagra And Melanoma
In recent years researchers have uncovered a potentially important pathway whereby PDE5A inhibitors (which include sildenafil– Viagra– and other drugs used to treat erectile dysfunction and pulmonary hypertension) could potentially increase the risk of developing melanoma. Now a new study provides early evidence showing an association between sildenafil and melanoma, though, like all observational studies, it is unable to demonstrate a cause-and-effect relationship. … Click here to read the full post on Forbes.     (Source: CardioBrief)
Source: CardioBrief - April 8, 2014 Category: Cardiology Authors: Larry Husten Tags: Prevention, Epidemiology & Outcomes Cialis erectile dysfunction Levitra melanoma PDE5A inhibitors Viagra Source Type: blogs

CoveredCA statistics (along with some random thoughts...)
Each week, CoveredCA puts out a website and call center activity report.  I thought it would be interesting to put together a consolidated table of their press releases.  Here's the table and my observations.  Key figures are in bold. Oct 1-5 Oct. 6-12 Oct 13-19 Oct 20-26 Oct27-Nov2 Unique visits to CoveredCA.com      986,705     602,539     486,678     543,300     511,552 Call volume   &n...
Source: InsureBlog - November 7, 2013 Category: Medical Lawyers and Insurers Source Type: blogs

Blind to women’s sexual health
A recent article published in partnership with The Investigative Fund and Newsweek questioned the existence of “female dysfunction,” as if to say, who cares about women’s sexual health? If you can’t “see” it, apparently it doesn’t exist. This is one-sided, inaccurate and disparaging of women. Why is it that when men are impotent it is taken seriously, but when women suffer from sexual dysfunction it is ridiculed and attributed to “Big Pharma’s” attempt to conjure a condition so they can make and sell a drug?  If Pharma is so bad, why do we depend upon them to research and manufacture drugs to prevent a...
Source: Disruptive Women in Health Care - May 16, 2013 Category: Health Medicine and Bioethics Commentators Authors: dw at disruptivewomen.net Tags: Aging Women's Health Sexual dysfunction Source Type: blogs

DTC Down the Drain
"Direct-to-consumer advertising, as we've known it, at least, is not the be-all and end-all of marketing prescription drugs to patients anymore," says Matthew Arnold in a new MM&M report with the provocative title "DTC Drain" (find it here). Yes, and the spending trend shows it -- DTC ad spending decreased 12% in 2012 compared to 2011 (see "DTC Not As Dead As We Thought... But Digital Ad Spending Down One-Third!")I took MM&M's title a step further and increased the alliterative appeal by adding "Down" as in the following photo, which appeared in the MM&M report (sans the words):The tubs image, of cour...
Source: Pharma Marketing Blog - April 4, 2013 Category: Pharma Commentators Tags: Erectile Dysfunction Cialis Viagra DTC Advertising Source Type: blogs

Sex, Lies & DTC Advertising For Impotence Pills
Several years ago, the drugmakers that sell impotence pills convinced Congress that federal regulations were not required to ensure objectionable ads would not be seen by children. However, a new study charges that industry efforts to regulate direct-to-consumer advertising have been a “ruse” designed to deflect criticism and block Congress from intervening. From 2006 to 2010, when DTC advertising for erectile dysfunction pills rose 62 percent, to $324.3 million, the study found a “consistent pattern” in which drugmakers failed to comply with so-called guiding principles that were propagated by the ...
Source: Pharmalot - February 20, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Bayer Cialis Eli Lilly Erectile Dysfunction GlaxoSmithKline Impotence Leviitra Merck Pfizer Viagra Source Type: blogs